A COVID-19 vaccine research group is recruiting 500 more volunteers for phase two clinical trials. Volunteers will have a 50 percent chance of getting a medium dose injection, a 25 percent of getting a low dose injection, and a 25 percent chance of getting a placebo. High-doses are excluded as phase one test results show it is more likely to cause a temporary fever.